Table 2.
Summary of Tumors Tested for MDM2 Amplification Status by FISH and CISH
| Case No. | Age | Gender | Diagnosis | Tumor Category | FISH Ratio | Status by FISH | CISH Ratio | Status by CISH |
|---|---|---|---|---|---|---|---|---|
| 1 | 26 | F | Lipoma | Benign | 1.01 | Not amplified | 0.92 | Not amplified |
| 2 | 44 | M | Lipoma | Benign | 0.98 | Not amplified | 0.98 | Not amplified |
| 3 | 38 | M | Lipoma | Benign | 0.95 | Not amplified | 0.99 | Not amplified |
| 4 | 54 | M | Lipoma | Benign | 1.03 | Not amplified | 1.04 | Not amplified |
| 5 | 71 | F | Lipoma | Benign | 0.96 | Not amplified | 1.02 | Not amplified |
| 6 | 42 | M | Lipoma | Benign | 0.97 | Not amplified | Unknown | Unknown |
| 7 | 81 | F | Benign lipomatous tumor | Benign | 0.97 | Not amplified | 0.95 | Not amplified |
| 8 | 47 | F | Benign lipomatous tissue | Benign | 0.98 | Not amplified | 1.01 | Not amplified |
| 9 | 43 | F | Hibernoma | Benign | 0.92 | Not amplified | 0.95 | Not amplified |
| 10 | 68 | F | Intramuscular lipoma | Benign | 1.02 | Not amplified | 1.05 | Not amplified |
| 11 | 60 | M | Mature fibroadipose tissue | Benign | 1.10 | Not amplified | 0.95 | Not amplified |
| 12 | 46 | F | Myolipoma | Benign | 0.94 | Not amplified | 1.03 | Not amplified |
| 13 | 25 | F | Well differentiated lipomatous tissue | Benign | 1.02 | Not amplified | 0.97 | Not amplified |
| 14 | 50 | M | Well differentiated lipomatous tumor with overlap features of spindle cell lipoma and cellular angiofibroma | Benign | 0.99 | Not amplified | 1.01 | Not amplified |
| 15 | 51 | F | Lipomatous areas with minimal atypia | Benign | 1.01 | Not amplified | 1.03 | Not amplified |
| 16 | 51 | F | Lipomatous neoplasm, minimal cytologic atypia | Benign | 1.02 | Not amplified | 1.01 | Not amplified |
| 17 | 48 | M | Atypical lipoma | Benign | 1.02 | Not amplified | 0.98 | Not amplified |
| 18 | 75 | M | Lipomatous tumor, scattered atypical cells | Benign | 1.00 | Not amplified | 1.05 | Not amplified |
| 19 | 43 | F | Lipomatous tumor, scattered moderate nuclear atypia | Benign | 1.10 | Not amplified | 1.03 | Not amplified |
| 20 | 61 | F | Myxoid LPS | Malignant | 1.01 | Not amplified | 1.21 | Not amplified |
| 21 | 40 | F | Myxoid LPS | Malignant | 0.95 | Not amplified | 1.12 | Not amplified |
| 22 | 62 | F | Myxoid LPS | Malignant | 0.98 | Not amplified | 0.90 | Not amplified |
| 23 | 65 | F | Myxoid LPS | Malignant | 1.04 | Not amplified | 0.95 | Not amplified |
| 24 | 37 | F | ALT/Well differentiated myxoid liposarcoma | Malignant | 1.00 | Not amplified | 0.99 | Not amplified |
| 25 | 75 | M | Liposarcoma, mixed type (myxoid and high grade round cell) | Malignant | 0.70 | Not amplified | 0.88 | Not amplified |
| 26 | 80 | F | ALT‐WDLPS | Malignant | 1.01 | Not amplified | 1.84 | Not amplified |
| 27 | 64 | M | ALT‐WDLPS | Malignant | 1.00 | Not amplified | 0.96 | Not amplified |
| 28 | 62 | F | ALT‐WDLPS | Malignant | 1.45 | Not amplified | CBQ | Amplified |
| 29 | 58 | F | ALT‐WDLPS | Malignant | CBQ | Amplified | CBQ | Amplified |
| 30 | 60 | M | ALT‐WDLPS | Malignant | CBQ | Amplified | CBQ | Amplified |
| 31 | 68 | F | ALT‐WDLPS | Malignant | CBQ | Amplified | CBQ | Amplified |
| 32 | 58 | M | ALT‐WDLPS | Malignant | CBQ | Amplified | CBQ | Amplified |
| 33 | 62 | M | ALT‐WDLPS | Malignant | CBQ | Amplified | CBQ | Amplified |
| 34 | 62 | F | ALT‐WDLPS | Malignant | CBQ | Amplified | CBQ | Amplified |
| 35 | 81 | M | ALT‐WDLPS | Malignant | CBQ | Amplified | CBQ | Amplified |
| 36 | 54 | M | DDLPS | Malignant | CBQ | Amplified | CBQ | Amplified |
| 37 | 53 | M | DDLPS | Malignant | CBQ | Amplified | CBQ | Amplified |
| 38 | 57 | F | Liposarcoma with low‐grade dedifferentiation | Malignant | CBQ | Amplified | CBQ | Amplified |
| 39 | 52 | M | Pleomorphic high‐grade sarcoma | Malignant | CBQ | Amplified | CBQ | Amplified |
| 40 | 55 | M | Undifferentiated pleomorphic high‐grade liposarcoma | Malignant | CBQ | Amplified | 1.05 | Not amplified |
| 41 | 50 | F | Spindle cell melanoma | Malignant | 0.9 | Not amplified | Unknown | Unknown |
CBQ, cannot be quantitated.